BICO Group AB Class B (BICO) AI Stock Analysis

• Market Cap: $1.49B
• Dividend Yield: N/A
• Average Volume (3M): 497.20K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.49
• Revenue Growth: -21.56%
• EPS Growth: 70.41%
• Country: SE
• Employees: 695
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -2.50
• Shares Outstanding: 69,074,900
• 10 Day Avg. Volume: 348,330
• 30 Day Avg. Volume: 497,203
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 2.23
• Enterprise Value/Revenue: 1.67
• Enterprise Value/Gross Profit: 3.09
• Enterprise Value/Ebitda: 11.22
• 1Y Price Target: $35.98
• Price Target Upside: 70.85% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 54 Neutral
• Price Target: kr36.00 ▲(70.94% Upside)

The overall score reflects a company with strong revenue growth and strategic initiatives but also significant challenges including negative profitability, valuation concerns, and macroeconomic headwinds. While financial performance and cash flow management show promise, technical analysis and valuation metrics highlight current vulnerabilities.

BICO Group AB Class B Business Overview & Revenue Model

Company Description

BICO Group AB (publ) operates as a bio convergence company in North America, Europe, Asia, and internationally. It operates through two segments, Laboratory Solutions and Bioautomation. The Laboratory Solutions segment offers 3D bioprinters, hybrid microscopes, single-cell dispensing instruments, and liquid handling instruments, as well as services and related consumables, such as bioinks, reagents, microscope lenses, software, printheads, and 3D reconstructed human tissues for applications in regulatory testing. This segment also offers services in 3D cell culture, 3D tissue imaging, multiplex imaging, and digital pathology to pharmaceutical and biotechnology companies. The Bioautomation segment offers products in precision dispensing and biosensor technology to the industrial customer; and diagnostics automation and advanced robotics solutions for the medical and diagnostic industries. In addition, it offers core industrial ecosystem, tissue engineering, multi-omics, cell line development, and diagnostics solutions. It primarily serves medical, pharmaceutical, and cosmetic industries. The company was formerly known as Cellink AB (publ) and changed its name to BICO Group AB (publ) in August 2021. BICO Group AB (publ) was founded in 2016 and is based in Gothenburg, Sweden.

How the Company Makes Money

BICO Group AB generates revenue primarily through the sale of its bioprinting, biosciences, and bioautomation products and services. These offerings are marketed to academic institutions, pharmaceutical companies, and clinical research organizations that require advanced tools for research and development purposes. The company also benefits from strategic partnerships and collaborations with key industry players, which help expand its market reach and drive sales. Additionally, BICO may generate income from licensing agreements and providing specialized consulting services to its clients, further contributing to its revenue streams.

BICO Group AB Class B Financial Statement Overview

Summary

BICO Group AB demonstrates robust revenue growth with a focus on improving operational efficiency, as seen in the positive EBITDA margin. However, challenges with profitability and maintaining stockholders' equity persist. Strong cash flow management with positive free cash flow trends suggests potential improvement, but reducing losses and managing debt remain crucial.

Income Statement

The company shows strong revenue growth over the years, but profitability is a concern. The TTM (Trailing-Twelve-Months) data indicates a negative net profit margin and EBIT margin, reflecting ongoing operational challenges. However, the EBITDA margin is positive, suggesting some operational efficiency. The increase in gross profit margin indicates improved cost management.

Balance Sheet

The balance sheet reveals a moderate debt-to-equity ratio and a reasonable equity ratio, indicating a stable financial structure. However, the decrease in stockholders' equity over time could be a concern if it continues. The company needs to improve its return on equity, which is currently negative due to ongoing losses.

Cash Flow

The cash flow statement shows a positive trend with improving free cash flow and operating cash flow. The free cash flow to net income ratio and operating cash flow to net income ratio are positive, indicating effective cash management despite negative net income. The company has reduced its financing cash flow significantly, which might impact future liquidity.

Breakdown	TTM	Dec 2024	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	1.99B	1.95B	2.24B	1.26B	176.79M	105.46M
Gross Profit	1.08B	1.01B	1.83B	1.00B	163.62M	91.36M
EBITDA	296.10M	437.60M	322.30M	31.80M	-39.50M	5.82M
Net Income	-211.30M	-5.50M	-835.70M	-229.20M	-61.89M	581.00K
Balance Sheet
Total Assets	4.74B	5.48B	10.20B	9.75B	1.65B	603.12M
Cash, Cash Equivalents and Short-Term Investments	596.50M	598.00M	925.20M	1.48B	995.80M	109.12M
Total Debt	1.41B	1.76B	1.85B	1.61B	62.49M	600.00K
Total Liabilities	2.08B	2.48B	3.26B	2.95B	126.74M	53.48M
Stockholders Equity	2.64B	2.98B	6.91B	6.77B	1.52B	549.64M
Cash Flow
Free Cash Flow	193.30M	72.70M	-799.00M	-676.20M	-154.12M	-51.56M
Operating Cash Flow	252.30M	158.40M	-269.40M	-409.20M	-71.82M	-15.82M
Investing Cash Flow	165.80M	128.00M	212.90M	-4.45B	-200.90M	-110.20M
Financing Cash Flow	-484.20M	-200.70M	455.30M	4.90B	1.04B	140.33M

BICO Group AB Class B Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 21.06
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BICO, the sentiment is Negative. The current price of 21.06 is below the 20-day moving average (MA) of 23.07, below the 50-day MA of 30.05, and below the 200-day MA of 33.71, indicating a bearish trend. The MACD of -2.40 indicates Negative momentum. The RSI at 26.93 is Positive, neither overbought nor oversold. The STOCH value of 14.29 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:BICO.

BICO Group AB Class B Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CEVI	75 Outperform	4.25B	28.08	17.25%	1.40%	3.45%	4.22%
HUM	70 Neutral	2.15B	10.06	6.86%	2.42%	6.74%	75.70%
PAX	62 Neutral	1.71B	154.27	2.01%	―	14.28%	-68.33%
XVIVO	57 Neutral	5.77B	51.81	5.32%	―	17.78%	-7.83%
BICO	54 Neutral	$1.49B	―	-15.03%	―	-21.56%	70.41%
XSPRAY	47 Neutral	2.15B	-7.53	0.00%	―	0.00%	0.57%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

BICO Group AB Class B Corporate Events

BICO Group COO Marius Balger Departs

BICO Group AB has announced the departure of its Chief Operating Officer, Marius Balger, who has decided to pursue new opportunities outside the company. During his tenure since March 2023, Balger has significantly contributed to strengthening BICO’s global operations, implementing key initiatives that enhanced operational excellence. The company has an interim solution in place for the COO duties, ensuring continuity in its operations.

BICO Group AB Announces Key Resolutions at Annual General Meeting

At the Annual General Meeting, BICO Group AB resolved several key issues, including the adoption of the 2024 financial statements and the decision not to distribute dividends, opting instead to carry forward profits. The meeting also saw the re-election and election of board members, the approval of remuneration guidelines, and the implementation of new incentive programs designed to align key personnel interests with those of shareholders, potentially impacting the company’s ability to attract and retain talent.